Introduction
Over the past 5 years, umbilical cord blood (UCB) has become an important alternative source of hematopoietic stem cells for transplantation and gene transduction protocols, 1 since it is highly enriched for hematopoietic progenitors compared to bone marrow (BM) and adult peripheral blood (PB). 2, 3 However, due to the small volume and the high variability in stem cell numbers, a single UCB collection is often considered to be insufficient to secure marrow engraftment in adults, and so far, UCB transplantations have been limited to pediatric patients. Since UCB is available without donor risk, and has the advantage of reduced risks for graft-versus-host disease and infections, 3 it would be of great benefit if UCBderived long-term repopulating cells could be expanded in vitro. Such expansion studies might also improve our current understanding of the regulation of hematopoiesis and open the way for new strategies in the treatment of hematological disorders and for the optimization of PB mobilization protocols.
High proliferation rates accompanied by a rapid differen-tiation of primitive progenitor cells have been obtained with previous ex vivo expansion systems. [4] [5] [6] More recently, several groups have reported the qualitative and quantitative maintenance in vitro of engrafting stem cells, [7] [8] [9] and there is now evidence for a slight, but net increase in SCID repopulating cells during ex vivo culture. [10] [11] [12] However, the culture conditions and growth factor combinations used to promote stem cell maintenance and proliferation differ substantially, although many of the cytokine cocktails include FLT3 ligand (FL), KIT ligand (SCF) and IL-3. 11, [13] [14] [15] [16] [17] [18] Recent studies indicate that the c-mpl ligand, TPO, may also be a potent agent to support the survival and expansion of primitive hematopoietic progenitors. [19] [20] [21] [22] [23] In fact, Piacibello et al 24, 25 have described the extensive amplification of primitive human UCB-derived progenitor cells, using the single growth factor combination of FL and TPO.
Other reports emphasize an important role for the multifunctional cytokine IL-6 in the regulation of hematopoiesis. 11, 22, 26, 27 This pleiotropic molecule has been shown to act synergistically with IL-3 and SCF to enhance the proliferation of human hematopoietic progenitor cells. 28, 29 The intracellular portion of the IL-6R␣ is very short and signal transduction requires an associated 130-kDa (gp130) molecule that lacks IL-6 binding activity. 30 This transducer unit is also shared by receptors for IL-11, leukemia inhibitory factor (LIF), oncostatin M (OM), ciliary neurotrophic factor (CNTF), and cardiotrophin 1 (CT-1), and therefore explains the overlapping activities of these cytokines. Binding of IL-6 or IL-11 to their respective receptors leads to the homodimerization and activation of gp130, while LIF, OM, CNTF, and CT-1 induce a gp130 heterodimerization. 30 Interestingly, gp130-deficient mouse embryos show greatly diminished numbers of hematopoietic progenitors, thereby underlining the importance of this signal transduction pathway in the regulation of hematopoiesis. 31 Gp130 is ubiquitously expressed on blood progenitors, whereas the expression of IL-6R␣ seems to be limited to approximately 30-50% of CD34
+ UCB and 80% of CD34 + PB cells. 32, 33 These CD34 + IL-6R␣ + cells are predominantly myeloid precursors. In contrast, erythroid and megakaryocytic progenitors as well as long-term culture initiating cells (LTC-IC) have been found to be enriched in the CD34 + IL-6R␣ − UCB fraction and to lack responsiveness to IL-6. 32 However, a soluble form of IL-6R␣ (sIL-6R) has been shown to complex with IL-6 and to act agonistically on gp130 + IL-6R␣ − cells.
34
In vitro short-term culture studies, using a combination of IL-6 and sIL-6R, report a dramatic expansion of primitive hematopoietic cells as well as an erythropoietin (EPO)-independent erythrocyte production, and a trilineage blood cell generation in the presence of SCF and IL-3. 32, 35, 36 Similar results have been obtained using a combination of IL-6, sIL-6R and FL although the synergistic action was weaker than with SCF. 37 Recently, the complex of IL-6 and sIL-6R has also been shown to stimulate megakaryopoiesis in the presence of SCF or IL-3 and TPO. 38 The importance of this IL-6/sIL-6R complex is further demonstrated in IL-6/sIL-6R double transgenic mice, which develop a marked extramedullary hematopoiesis in the spleen and liver. It has been hypothesized that the IL-6/sIL-6R complex is able to expand primitive resident stem cells in these primary hematopoietic organs in vivo. 34, 39, 40 An important objective of the present study was to investigate the potential benefit of the new designer recombinant IL-6 and sIL-6R fusion protein, H-IL-6, for the ex vivo expansion of hematopoietic UCB progenitors. Using stroma-free and stroma-supported long-term cultures, we compared several cytokine combinations in the presence or absence of this chimeric protein or with IL-6 and estimated the progenitor output by multiparameter FACS analyses and CAFC (cobblestone area forming cell) assays. Our results indicate that H-IL-6 effectively synergizes with FL and TPO with or without SCF for the expansion of CD34 + and CD34 + AC133 + progenitors including primitive week 6 CAFC. However, in this respect, the action of the H-IL-6 fusion peptide was less potent than that of the full-length recombinant human IL-6 under our culture conditions. 
Materials and methods

Cells
Cell purification
Fresh or thawed UCB MNCs were purified for AC133 + or CD34 + cells using the VarioMACS Immunomagnetic Separation System (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's protocol. The purity assessed by FACS analysis ranged between 75% (single-selected) and 99% (double-selected). The recovered cells were either directly cultured or further purified for CD34
− and CD34 − AC133 + cells by FACS sorting using standard protocols (see below).
Antibodies
The following monoclonal antibodies (MoAbs) were used in this study: AC133-PE (clone AC133; Miltenyi Biotec), CD34-APC, -PE, -FITC (clone 581), CD38-PE, -FITC (clone T16), CD14-PE (clone RMO52), CD15-FITC (clone 80H5), CD19-PE (clone J4.119), CD20-FITC (clone B9E9), CD33-PE (clone D3HL60.251), CD41-FITC (clone P2), CD45-PE, -FITC (clone J. 33 
FACS analysis and FACS sorting
FACS analyses and FACS sorting were performed on a FACSCalibur flow cytometer (Becton Dickinson) equipped with an argon laser tuned to 488 nm and a helium neon laser tuned to 630 nm using Cellquest software (Becton Dickinson). Cell labeling was carried out either in 96-well round-bottom plates (non-sterile staining) or in sterile polystyrene tubes. Immunoglobulin binding sites were blocked with 10% (vol/vol) human serum and the cells were labeled on ice with the respective antibodies for 25 min in HBSS containing 0.5% (wt/vol) BSA ± 0.1% (wt/vol) sodium azide. The stained cells were washed twice, resuspended in HBSS, and 1 g/ml 7-aminoactinomycin D (7-AAD; Molecular Probes, Leiden, The Netherlands) was added for viable cell selection prior to analysis and sorting. Non-specific background staining was determined using cells labeled with isotype-matched control antibody conjugates. Sorted cells were collected in 50 ml tubes pre-filled with 5 ml FCS and one sorted sample per sorting gate was re-analyzed to verify cell purity (85-97%).
Stroma-free cultures
Cells were cultured in Cell Gro SCGM (Cell Gro; Boehringer Ingelheim Bioproducts, Verviers, Belgium) supplemented with 10% (vol/vol) FCS or 10% (vol/vol) human AB serum. The medium was supplemented with 10 −4 M ␤-mercaptoethanol (␤-ME; Merck, Darmstadt, Germany), 100 U/ml penicillin, 50 g/ml streptomycin (Gibco-BRL), and various recombinant human growth factor combinations at final concentrations of 100 ng/ml rhFL (Amgen, Thousand Oaks, CA, USA), 10 ng/ml huTPO (Genetech, San Francisco, CA, USA), 1-20 ng/ml H-IL-6, 41 100 ng/ml rhIL-6 (Genetics Institute, Cambridge, MA, USA), 100 ng/ml huSCF (Amgen) and 50 U/ml rhIL-11 (Genetics Institute). The cytokines were added weekly, except for FL and TPO, which were added twice per week. 5 × 10 4
AC133
+ or CD34 + cells were plated in six-well plates (Corning Costar, NY, USA) in duplicate or triplicate in 1 ml medium with the respective cytokine combinations to initiate the cultures. At weekly intervals, the cells were harvested by rinsing the wells twice with HBSS. All cells from each group were pooled, demi-depopulated by reducing the volume by 50% (or 33% at week 1), and re-plated in fresh medium. The remaining cells were analyzed for viability (using trypan blue), cell number, immunophenotype, and for CAFC and CFC content. Cell samples were also cytocentrifuged at various time points and stained with May-Grü nwald-Giemsa for morphological analysis. Single-cell cultures were performed in roundbottom 96-well plates (Falcon, Becton Dickinson). Sorted CD34 +
CD38
− cells were diluted to a concentration of 0.7 cells/100 l in CellGro SCGM with 10% (vol/vol) FCS. The cell suspension was mixed well, aliquoted, supplemented with the various cytokine combinations and seeded into microtiter plates at a volume of 100 l per well (60 wells per plate). Fresh medium and cytokines were added every 10 days. The number of cells in the single wells was scored weekly using an inverted microscope. Cluster and clones up to 100 cells were counted, larger clones were estimated according to their surface occupancy. All cultures were maintained in a humidified atmosphere of 10% CO 2 at 37°C.
Stroma-contact cultures
AC133
+ cells were seeded in duplicate at a concentration of 5 × 10 4 cells per ml in six-well plates previously coated with murine FBMD-1 stromal cells. Every week the cells were harvested by collecting first the non-adherent fraction and then carefully trypsinizing the adherent cells. Both fractions were pooled and suspended in fresh CellGro SCGM medium without insulin (supplemented with penicillin/streptomycin and ␤-ME). Half of the volume was re-plated on a new confluent FBMD-1 layer, and supplemented with the respective cytokines, while the other half was used for analyses.
CAFC and CFC assays
CAFC assays were performed as follows: confluent stromal layers of the mouse FBMD-1 cell line in 96-well plates were overlaid with primary MACS-separated or ex vivo cultured cells in a limiting dilution assay. Twelve dilutions, two-fold apart, with 8-15 replicate wells were prepared in IMDM (Iscove's modified Dulbecco's medium; BioWhittaker, Boehringer Ingelheim, Verviers, Belgium) supplemented with 1% (vol/vol) Glutamax (GibcoBRL), 10 −4 M ␤-ME, 100 U/ml penicillin, 50 g/ml streptomycin, 10% FCS (Summit), 5% horse serum (Integro, Zaandam), 10 −5 M hydrocortisone 21-hemisuccinate (Sigma), 10 ng/ml rhIL-3 (Gist Brocades, Delft, The Netherlands) and 20 ng/ml rhG-CSF (Amgen). Half of the medium was replaced weekly with fresh medium supplemented with cytokines as described above. The cell input values ranged between 100 and 20 000 cells per well. The percentage of wells with at least one cobblestone area (minimum of five cells) beneath the stroma layer was determined after 2, 4 and 6 weeks, and CAFC frequencies were calculated using Poisson statistics. The clonal cell cultures were plated in duplicate in 35-mm petri dishes (Becton Dickinson) in 1 ml methylcellulose-based medium consisting of: 1.2% methylcellulose (Methocel, Stade, Germany), 30% (vol/vol) FCS, 10 −4 M ␤-ME, 1 U/ml recombinant human (rh) EPO (Boehringer Mannheim, Mannheim, Germany), 10 ng/ml rhIL-3 (Gist Brocades), 5 ng/ml rhGM-CSF (Genetics Institute), 20 ng/ml rhG-CSF (Amgen), 100 ng/ml murine rSCF (Genetics Institute) in IMDM. AC133
+ and CD34 + cells were plated at a concentration of 50 cells per dish and cultured cells at a concentration of 100 to 20 000 cells per dish. Granulocyte/macrophage colony-forming (CFU-G/M) progenitor numbers were scored after 14 days at 37°C and 5% CO 2 .
Statistical analysis
Results were expressed as means (± s.d.) of data obtained from three or more experiments, unless otherwise specified. Significance levels were determined using the Student's t-test.
Results
The H-IL-6 fusion protein increases the expansion of CD34
+ and CD34
in the presence of FL and TPO
The combination of FL and TPO has recently been described as inducing an extensive amplification and 'self-renewal' of UCB-derived 'stem cells' under serum-containing conditions. 24, 25 We therefore analyzed various concentrations of the H-IL-6 fusion protein for its ability to enhance progenitor output in liquid cultures supplemented with FL and TPO in the presence of 10% serum. As shown in Figure 1 , the expansion of CD34
+ progenitor cells over a 4 week period increased in a H-IL-6 dose-dependent manner, reaching maximal values at 3 ng/ml H-IL-6, when assayed using FACS analyses. As a single agent H-IL-6 failed to induce an expansion of CD34 + cells (data not shown). In order to evaluate the effect of the fusion protein in more detail, AC133
+ and CD34 + UCB cells, separated using MiniMACS columns, were grown in FL and TPO containing suspension cultures in the presence or absence of H-IL-6 in a defined serum-free medium (CellGro SCGM) supplemented with FCS concentrations varying from 0% to 20%. The progenitor output over a period of 5-6 weeks was estimated using CFC and CAFC assays and FACS analyses. The proliferation of nucleated cells and CD34
+ cells increased in an FCS concentration-dependent manner reaching plateau values at 10% FCS. Figure 2 shows the results of a representative experiment analyzing the expansion of nucleated cells, CD34
+ cells and CD34 + AC133 + cells from AC133-separated or CD34-separated UCB cells during 5-6 weeks of culture in the presence of 10% FCS and FL plus TPO with or without 3 ng/ml H-IL-6. In three independent experiments, FL and TPO induced an 86.04 ± 45.10-fold increase in nucleated cell numbers, a 10. + cells from AC133-separated (--) and CD34-separated (----) pooled UCB cells in the presence of FL (100 ng/ml) and TPO (10 ng/ml) with or without H-IL-6 (3 ng/ml).
(ie a respective 4.5-fold, 6.5-fold and six-fold higher expansion than for FL plus TPO alone, P р 0.01 in all cases). The expansion potential of the CD34-separated UCB cells, derived from the same donor pools, was lower than that of the AC133-separated cells, and the addition of H-IL-6 to the combination of FL and TPO enhanced the CD34 + and CD34 + AC133 + output only three-and four-fold, respectively. FL and TPO, in the presence or absence of H-IL-6, were not sufficient to increase total cell numbers for longer than 2 weeks at serum concentrations lower than 5% (data not shown). Furthermore, no maintenance or expansion of primitive week 6 CAFC could be obtained using this medium without serum addition (data not shown). The growth-promoting effect of H-IL-6 on progenitor cells is also illustrated in a typical FACS analysis in Figure 3 . While the percentage of CD34 + AC133 + and CD34 + AC133 − cells rapidly decreased after 1 week of culture if only FL and TPO were present, a slower decrease was found in cultures supplemented with the H-IL-6 fusion protein. In three independent experiments, the percentage of CD34 + cells after 6 weeks of culture was 7.2 ± 4.2-fold higher in the presence of H-IL-6 than in its absence (P = 0.001).
H-IL-6 improves the CFU-G/M and CAFC expansion in the presence of FL and TPO
The CAFC assay allows the frequency analysis of very primitive (CAFC week 5-8) as well as more mature progenitor cells (CAFC within the first 4 weeks), while the CFC assay determines the frequency and lineage commitment of colony-forming cells. 42 As shown in Table 1 , the combination of FL and TPO induced only a small expansion of week 6 CAFC (twoto four-fold) from AC133
+ UCB cells during 3 weeks of ex vivo culture, but was not sufficient to maintain week 4 and week 6 CAFC over 6 weeks of culture. In contrast, the addition of H-IL-6 resulted in a 6.92 ± 2.61-fold expansion of week 6 CAFC during 6 weeks of culture (P = 0.001). The highest increase was obtained for the more mature progenitor fractions, with the total expansion of week 2 CAFC being 8.1-fold higher (P = 0.001) and the expansion of CFU-G/M being threeto four-fold higher in the presence of H-IL-6 (P = 0.001).
Gp130-signaling and long-term expansion
To investigate the effect of H-IL-6 in long-term cultures, AC133
+ UCB cells were grown under stroma-free, serum-containing or stromal-supported, serum-free conditions for up to 12 weeks in the presence or absence of the H-IL-6 fusion protein or IL-6 and various combinations of FL, TPO and SCF. A representative experiment with a single pool of AC133-separated UCB cells is shown in Figure 4 .
Under stroma-free, serum-containing conditions, the twofactor combination FL and SCF induced a 190 ± 32.5-fold expansion of nucleated cells, a 15.5 ± 3.5-fold expansion of CD34 + cells, and a 5.5 ± 0.1-fold expansion of CD34 + AC133 + cells during the first 2 to 4 weeks of culture before declining. The addition of H-IL-6 to FL and SCF increased the number of total nucleated cells a further two-fold (1.85 ± 0.92-fold, P = 0.1; Figure 4a ). Interestingly, the highest propagation was obtained for CD34 + cells with the expansion of these being 4.7 ± 1.9-fold higher (P = 0.049; Figure 4b Flow cytometric analyses of AC133-separated UCB cells before and during ex vivo culture with FL and TPO in the presence or absence of H-IL-6. Cells were stained with CD34-APC and AC133-PE. The quadrants were set according to negative control samples labeled with IgG1-PerCP and IgG1-PE. AC133 + UCB cells were grown in serum-containing cultures supplemented with FL and TPO in the presence or absence of H-IL-6. After 3 and 6 weeks of culture fractions of cells were plated in methylcellulose for CFU assays and stroma-coated 96-well plates for CAFC assays. The colony assays were initiated with 400-1000 cells per ml, the CAFC assays with 750-5000 cells in the first dilutions, and analyzed as described in Materials and methods. Results are means ± s.d. of n = 3 experiments.
The two-factor combination FL and TPO induced a twofold lower expansion of nucleated cells and CD34
+ cells than FL plus SCF under stroma-free conditions during the early phases of the culture. The addition of the H-IL-6 fusion protein to FL and TPO increased the number of CD34 + AC133 + cells to the same level as FL, SCF plus H-IL-6 but resulted in a threefold lower expansion of CD34 + cells, which were negative for AC133 (data not shown). Interestingly, IL-6 showed a greater synergistic effect with FL and TPO for the long-term expansion of UCB progenitors than the H-IL-6 fusion protein. In four different experiments, IL-6 induced, during the first 6 weeks of culture, a 1.96 ± 0.64-fold higher expansion of nucleated cells (P = 0.039), a 2.28 ± 0.33-fold higher expansion of CD34 + cells (P = 0.037) and a 2.74 ± 0.28-fold higher expansion of CD34 + AC133 + cells (P = 0.022) than the H-IL-6 fusion protein in combination with FL and TPO. While the progenitor expansion dropped after 5-7 weeks in the H-IL-6 supported cultures, a long-term expansion could be sustained in the presence of FL, TPO and IL-6 resulting in an up to 10-fold higher propagation of CD34 + cells over 12 weeks of culture. Co-culture with the murine FBMD-1 stromal cell line in the absence of serum greatly increased the progenitor output in cultures containing FL and TPO. Although the addition of H-IL-6 to FL and TPO induced a further 10-fold increase in CD34 + numbers, the synergistic effect of the fusion protein for the propagation of CD34 + and CD34 + AC133 + cells was approximately four-fold lower than that of IL-6 under the same conditions, while the increase in nucleated cells differed only by a factor of 2.5-fold between IL-6 and the H-IL-6 fusion protein (n = 2).
The benefit of the full length recombinant IL-6 compared to the designer protein was also exemplified by the finding that IL-6 was more potent in enhancing the expansion of week 6 CAFC in the presence of FL and TPO. A preliminary but direct comparison showed an 18.5 ± 3.9-fold (mean ± s.d. of Poisson analysis) increase in primitive week 6 CAFC after 6 weeks of culture with FL, TPO and IL-6 in the absence of stroma, while in the presence of FL, TPO and H-IL-6 week 6 CAFC were only 4.6 ± 1.8-fold higher than the input. Stroma-contact greatly increased the expansion of week 6 CAFC in the presence of FL and TPO, and the addition of IL-6, or to a lesser extent H-IL-6, further enhanced the number of these primitive progenitors. The effect of stroma on the propagation of primitive progenitor cells is described in more detail in Kusadasi et al (manuscript in preparation).
Lineage commitment of ex vivo expanded cells in the presence of gp130 signaling
FL is known to stimulate the growth/differentiation of myelo/monocytic cells 18 while TPO has been shown to regulate megakaryocyte and platelet development. 20 Accordingly, approximately 25% of the in vitro expanded cells expressed the monocytic marker CD14, and up to 15% (9.6-14.8%) showed a CD33 
CD15
+ monocytic cells was more than two-fold higher in the stroma-supported than in the stroma-free cultures. A small fraction of CD71 + GlycA + erythroid progenitors (0.9-2.1%) could be detected after 2 weeks in the stroma-free cultures with FL and TPO ± IL-6 or H-IL-6. 0-0.5% erythroid cells were found in the other cultures (data not shown).
Phenotype of long-term expanded cells in the presence or absence of stroma
The immunofluorescence analysis of long-term expanded cells showed considerable differences between the stromafree and stroma-supported cultures. As shown in Figure 6 for the cytokine combination FL, TPO and IL-6, the percentage of CD34 + CD38 low/− and CD34 + CD90 + (hu Thy-1 antigen) cells
Figure 4
Expansion of nucleated (a), CD34 + (b) and CD34 + AC133 + (c) UCB cells in the presence or absence of H-IL-6 or IL-6. AC133-separated cells were cultured with the indicated cytokine combinations under either stroma-free serum-containing conditions or on the FBMD-1 stromal cell line without serum. The cells were demi-depleted weekly and re-plated as described.
Figure 5
Lineage commitment of AC133-separated UCB cells after 2 weeks of culture in serum-containing medium supplemented with the indicated cytokine combinations. The cells were labeled with different lineage-specific antibodies as described in Materials and methods, and analyzed on a FACSCalibur flow cytometer. after 12 weeks of culture was more than five times higher in the presence of stroma than in its absence. The percentage of CD34 + AC133 + cells was similar under both types of culture conditions. However, the majority of AC133 + cells were negative for CD34 under stroma-free conditions, while the expression of this antigen was, as on primary cells, restricted to the CD34 + fraction under stroma-supported conditions. Similar percentages (ie 5-7% CD34 
CD38
− cells into cell cycle in synergism with FL and TPO. The highest cloning frequency (52%) was found in the presence of FL, TPO plus SCF, which could not be further enhanced by IL-6 (50%). However, the number of viable clones decreased after 1 week of culture in the presence of FL, TPO and SCF, while a further recruitment of quiescent cells into cell cycle was observed with FL, TPO and IL-6. In addition, clones containing more than 5000 cells were found exclusively in the presence of IL-6, and were most frequent in the wells supplemented with the four-factor combination.
Discussion
In this study, we have examined the effect of a designer fusion protein of IL-6 and the soluble IL-6R, H-IL-6, on the ex vivo expansion of cord blood progenitors. As a single agent, the fusion protein failed to induce the propagation of UCBderived CD34
+ cells and CAFC, but synergized effectively and in a dose-dependent fashion with FL and TPO for the expansion of hematopoietic progenitor cells under both stroma-free and stroma-supported conditions. In addition, we have shown that IL-6 is more potent than the fusion protein in supporting the long-term propagation of UCB CD34 + AC133 + or CD34 + cells and CAFC in the presence of FL and TPO. Most data indicate that the proliferation of primitive hematopoietic progenitor cells requires co-stimulation by different regulatory factors. 43 Among the cytokines that are considered primary mediators in early hematopoiesis are FL and TPO. Primitive CD34 +
CD38
− rhodamine 123 low 4-hydroperoxycyclophosphamide (4-HC)-resistant cells respond to FL, 16 and several studies report a higher expansion of primitive progenitors in the presence of this cytokine. 15, 44 TPO has also been shown to enhance the recruitment of early hematopoietic progenitors into cell cycle and to increase the clonal growth and the viability of single CD34 +
− cells. 19, [21] [22] [23] Studies by Piacibello et al 24 have described a 1000-fold amplification of CD34 + cells and a 300-fold amplification of primitive LTC-IC after 3 to 6 weeks in serum-containing cultures supplemented with the single combination of FL and TPO. Using AC133 + or CD34
+ UCB cells, we were unable to reproduce such levels of expansion for CD34 + , CD34
+ AC133 + , CFC or CAFC subsets with FL and TPO under serum-containing conditions in our culture system. This may reflect differences in the sources of cytokines or the presence of uncharacterized factors in the sera. The addition of H-IL-6 increased the propagation of CD34 + cells more than six-fold over FL and TPO and further enhanced the proliferation of both CFC by three-to four-fold and primitive week 6 CAFC by two-fold during 6 weeks of culture. The fusion protein also acted synergistically with FL plus SCF and with FL, TPO plus SCF for the expansion of CD34
+ cells and week 6 CAFC both under serum-containing stroma-free and serum-free stroma-supported conditions.
Figure 6
Phenotype of cells cultured for 12 weeks in the presence of FL, TPO and IL-6 with or without stromal support. The cells were labeled with CD34-APC, CD38-FITC, and either AC133-PE or CD90-PE as well as 7-ADD to exclude dead cells. The cells were analyzed on a FACS-Calibur flow cytometer, and the quadrants were set according to control samples stained with isotype-matched control antibodies.
These results support and extend the studies of Sui et al 35 and Ebihara et al, 37 who tested a complex of the soluble IL-6R and IL-6 (IL-6/sIL-6R) in combination with SCF or FL in 3-week suspension cultures and methylcellulose clonal assays and demonstrated an increased expansion of multipotential and committed progenitors from UCB or BM-derived CD34 + cells. Kimura et al 33 did not find a significant colony formation from FACS-sorted CD34 + IL-6R + or CD34 + IL-6R − PB cells in the presence of SCF and IL6/sIL-6R alone, but a high proliferation of BFU-E and CFU-Mix colonies was induced in the IL-6R-negative fraction when IL-3 was added to this cytokine combination. Recently, Zandstra et al 45 reported a higher LTC-IC expansion in 1-week serum-free cultures of CD34 + CD38 − UCB cells stimulated by FL in combination with the IL-6/sIL-6R complex when compared to the combinations of FL plus TPO or FL, SCF, IL-6, IL-3 plus G-CSF. Since the half-life of this IL-6/sIL-6R complex is very short, high concentrations of the soluble IL-6R were needed to obtain effective stimulation. 34, 35, 45 In contrast, the H-IL-6 fusion protein has proven to be fully active at 100-to 1000-fold lower concentrations than the combination of IL-6 and IL-6R, 41 and in the present study 3 ng/ml H-IL-6 were found to be sufficient to induce maximal expansion of CD34 + cells in the presence of FL and TPO.
Fischer et al 41 were the first to test the effect of the H-IL-6 fusion protein on hematopoietic progenitors in short-term cultures. They found an increased expansion of CFU-GM when H-IL-6 or the IL-6/sIL-6R complex was added to the combination of SCF and IL-3 in 2-week cultures of CD34 + mobilized PB cells. Notably, under the same conditions, stimulation with IL-6 in place of the IL-6/sIL-6R complex resulted in a lower expansion of these committed progenitors. Sui et al 35, 36 also described an increased number of clonogenic progenitors generated from CD34 + UCB cells in the presence of SCF and IL-6/sIL-6R compared to SCF and IL-6. In their study, the IL-6/ sIL-6R complex stimulated in particular the expansion of erythroid and mixed colonies, while the number of CFU-GM was similar in the cultures supplemented with either IL-6 or the IL-6/sIL-6R complex. This is in line with the findings of Tajima et al, 32 who showed that erythroid progenitors and CFU-GEMM segregate with the CD34 
IL-6R␣
+ fraction, leading to the conclusion, that 'stem cells' or at least LTC-IC are IL-6R␣ negative, and cannot be stimulated by IL-6 alone. However, due to the low IL-6R␣ receptor expression, positive and negative fractions are not clearly distinguishable, and LTC-IC were not found to be restricted solely to the IL-6R-negative fraction. McKinstry et al, 46 using radiolabeled IL-6, also detected IL-6R␣ expression on 13% of primitive murine Rh low Lin
−
Sca1
+ kit + progenitors. Furthermore, murine 5FU-treated BM cells could be shown to proliferate in response to IL-6, SCF and IL-3. 47 Evidence that IL-6 complexed to the soluble IL-6R, but not IL-6 alone, may be able to stimulate early murine progenitors, comes from phenotypic analyses of mice single transgenic for either IL-6 or sIL-6R or double transgenic for both IL-6 and sIL-6R. 34, 39, 40 Interestingly, double transgenic mice developed a marked extramedullary hematopoiesis in the spleen and to a lesser extent the liver while the bone marrow cellularity was not significantly changed. The liver showed distinct foci with predominantly granulopoietic cells, while large numbers of erythrocytes, granulocytes and megakaryocytes were found equally distributed in the spleen. In addition, the number of primitive Lin
−
Sca1
+ kit + cells in the liver of double transgenic mice was increased from about 0.03% to 0.3% leading to the hypothesis that persisting fetal progenitor cells in spleen and liver can be recruited into proliferation by IL-6 in combination with the soluble IL-6R. However, as mentioned above, high concentrations of IL-6R seemed to be necessary to generate this effect, as Hirota et al 48 did not find hematological abnormalities in their IL-6 and sIL-6R transgenic mice with lower shedding levels of the membrane-bound IL-6R.
Interestingly, although the H-IL-6 fusion protein enhanced the expansion of AC133-separated hematopoietic progenitors with a variety of cytokine combinations in our culture system, IL-6 synergized more potently than the fusion protein with FL and TPO for the expansion of CD34 + and CD34 + AC133 + cells as well as of CAFC. This became more pronounced after prolonged ex vivo culture and may in part be due to the use of MACS-separated AC133 + UCB cells in preference to CD34-separated cells, which have been found to possess a lower expansion potential in our culture system. In this respect, the AC133 antigen is expressed on a subfraction of CD34 + cells, which comprises committed progenitors as well as LTC-IC and long-term repopulating cells. Our own unpublished data confirm that approximately 90% of the week 6 CAFC and approximately 80% of the CFU-GM can be recovered in the CD34 51 have reported, that STAT3-dependent gene transcription in HepG2 cells is about 10-fold higher after stimulation with H-IL-6 than after activation with IL-6. However, with increasing amounts of IL-6R␣ expression transgenic HepG2 cells became less sensitive to H-IL-6 while the response to IL-6 increased. Upregulation of IL-6R␣ expression during differentiation could therefore favor stimulation by IL-6 compared with H-IL-6 and indirectly mediate an as yet unknown growth promoting signal to more primitive progenitor cells.
While it has not as yet been shown that the direct stimulation of primitive CD34
− cells by the IL-6/ sIL-6R complex or the H-IL-6 fusion protein results in an expansion of long-term repopulating cells, IL-6 and IL-11 have been shown to synergize with other cytokines for the expansion of SCID repopulating cells (SRC). For instance, our recent studies indicate that IL-6 in combination with FL and TPO induces a 10-to 20-fold expansion of the ability of UCBderived SRC in serum-containing liquid cultures to repopulate the murine bone marrow (Kusadasi, manuscript in preparation), and also causes a higher expansion of week 6 CAFC than the combination of FL, TPO and SCF. In addition, a cytokine cocktail of IL-3, IL-6, G-CSF, SCF and FL is reported to support a two-fold expansion of NOD/SCID competitive repopulation units (CRU) from CD34 +
CD38
− UCB cells in serum-free suspension cultures. 11 Bhatia et al 12 have also described a two-to four-fold increase in SRC after short-term culture of CD34 +
− UCB cells with an IL-6 containing cytokine cocktail, while murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability could be expanded three-fold in serum-free medium containing IL-11, FL and SCF. 10 Notably, Peled et al 52 recently reported an upregulation of CXCR4 expression on CD34 + cells by SCF and IL-6. This receptor for the chemokine stromal cell-derived factor-1 (SDF-1) has been found to be critical for human stem cell engraftment and repopulation of NOD/SCID mice. Very recently, Piacibello et al 53 reported that CD34 + UCB cells could be expanded for up to 10 weeks in stroma-free cultures in the presence of FL, TPO, SCF and IL-6 without losing their in vivo repopulating potential.
In addition to the effects on primitive progenitor amplification, we observed that both IL-6 and H-IL-6 further enhanced the ex vivo expansion of megakaryocytic cells when combined with FL and TPO. This observation is important in a clinical setting where it is necessary to shorten the period of chemotherapy-induced thrombocytopenia, which is prolonged after UCB transplantation when compared to BM transplantation. 3 Contact with the murine stromal line FBMD-1 reduced the percentage of CD33 −
CD41
+ cells almost to background levels but, on the other hand, greatly enhanced the amplification of phenotypically and functionally primitive progenitor cells in the presence of FL and TPO with or without H-IL-6 or IL-6. Again, the highest progenitor expansion was found in the presence of IL-6. Interestingly, the phenotype of UCB progenitors expanded in co-culture with FBMD-1 stromal cells (in the presence or absence of serum) corresponded to the phenotype of primary progenitors with the expression of the AC133 antigen being restricted to the CD34 high subset.
In contrast, a fraction of CD34 low/− AC133 + cells, which most likely represents more mature myeloid progenitors, appeared and increased during liquid culture in the absence of stroma.
In conclusion, although the H-IL-6 fusion protein supported the ex vivo expansion of different progenitor populations in synergy with various cytokine combinations, no advantage over IL-6 could be observed in our culture system. Further studies are necessary to investigate whether this fusion protein can directly stimulate primitive marrow engrafting cells or if, like IL-6, it acts indirectly via accessory cells.
